Acefylline

Acefylline

SCHEMBL8402147

Cl.Cn1c(=O)c2c(ncn2CC(=O)O)n(C)c1=O

nearest known ligand 0.97

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Acefylline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
ADORA2B P29275 8/20 0.97
SMN1; SMN2 Q16637 3/20 0.71
LMNA P02545 3/20 0.67
MEN1 O00255 1/20 0.66
KMT2A Q03164 1/20 0.66
MAPT P10636 1/20 0.62
RXFP1 Q9HBX9 2/20 0.61
MAPK1 P28482 2/20 0.61
ALDH1A1 P00352 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acefylline SCHEMBL308514 0.98 ADORA2B (1.00) ADORA2BSMN1; SMN2LMNAMEN1KMT2A
Acefylline SCHEMBL18191994 0.98 ADORA2B (1.00) ADORA2BSMN1; SMN2LMNAMEN1KMT2A
Acefylline SCHEMBL1173152 0.93 ADORA2B (0.89) ADORA2BSMN1; SMN2LMNAMEN1KMT2A
Acefylline SCHEMBL356114 0.91 ADORA2B (0.85) ADORA2BSMN1; SMN2LMNAMEN1KMT2A
Acefylline SCHEMBL5493561 0.91 ADORA2B (0.85) ADORA2BSMN1; SMN2LMNAMEN1KMT2A
Acefylline SCHEMBL17204841 0.90 ADORA2B (0.84) ADORA2BSMN1; SMN2LMNAMEN1KMT2A
SCHEMBL17163939 0.87 ADORA2B (0.78) ADORA2BSMN1; SMN2LMNAMEN1KMT2A
SCHEMBL11531219 0.87 ADORA2B (0.78) ADORA2BSMN1; SMN2LMNAMEN1KMT2A
SCHEMBL9296212 0.85 ADORA2B (0.76) ADORA2BSMN1; SMN2LMNAKMT2AMAPT
SCHEMBL5468564 0.85 ADORA2B (0.76) ADORA2BSMN1; SMN2LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4652568-A Theophylline-7-acetic acid ester of d,l-trans-sobrerol having mucosecretolytic-fluidizing and antibronchospastic activity, a process for its preparation and pharmaceutical compositions thereof CAMILLO CORVI S.P.A. (IT) 1987-03-24 US claimed
US-5958933-A HAVING A GUANIDINO GROUP ALIPHATICALLY LINKED TO A XANTHINE GROUP, ADRENERGIC STIMULANTS NAFTCHI N ERIC (US) 1999-09-28 US disclosed
EP-0413751-A4 NEUROLOGICALLY ACTIVE COMPOUNDS 1992-07-22 EP disclosed
EP-0413751-A1 NEUROLOGICALLY ACTIVE COMPOUNDS NAFTCHI, N., Eric (US) 1991-02-27 EP disclosed
WO-1989010744-A1 NEUROLOGICALLY ACTIVE COMPOUNDS NAFTCHI N ERIC (US) 1989-11-16 WO disclosed
EP-0157284-B1 THEOPHYLLINE-7-ACETIC ACID ESTER OF D,L-TRANS-SOBREROL HAVING MUCOSECRETOLYTIC-FLUIDIZING AND ANTIBRONCHOSPASTIC ACTIVITY, A PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF CAMILLO CORVI S.p.A. (IT) 1989-08-09 EP disclosed
US-4652568-A Theophylline-7-acetic acid ester of d,l-trans-sobrerol having mucosecretolytic-fluidizing and antibronchospastic activity, a process for its preparation and pharmaceutical compositions thereof CAMILLO CORVI S.P.A. (IT) 1987-03-24 US disclosed
US-4652568-A Theophylline-7-acetic acid ester of d,l-trans-sobrerol having mucosecretolytic-fluidizing and antibronchospastic activity, a process for its preparation and pharmaceutical compositions thereof CAMILLO CORVI S.P.A. (IT) 1987-03-24 US disclosed
US-4584372-A Compound 3-(1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxopurine-7-acetyl-8-(2-phenylethyl)-1-oxa-3,8-diazaspiro-(4,5)decan-2-one and a process of preparation thereof VENERO AURELIO O (ES) 1986-04-22 US disclosed
EP-0157284-A2 Theophylline-7-acetic acid ester of d,l-trans-sobrerol having mucosecretolytic-fluidizing and antibronchospastic activity, a process for its preparation and pharmaceutical compositions thereof CAMILLO CORVI S.p.A. (IT) 1985-10-09 EP disclosed
EP-0157284-A2 Theophylline-7-acetic acid ester of d,l-trans-sobrerol having mucosecretolytic-fluidizing and antibronchospastic activity, a process for its preparation and pharmaceutical compositions thereof CAMILLO CORVI S.p.A. (IT) 1985-10-09 EP disclosed